Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Net Margin (2018 - 2025)

10x Genomics (TXG) has disclosed Net Margin for 8 consecutive years, with 9.79% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 1992.0% to 9.79% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6.77% through Dec 2025, up 2313.0% year-over-year, with the annual reading at 6.77% for FY2025, 2313.0% up from the prior year.
  • Net Margin hit 9.79% in Q4 2025 for 10x Genomics, up from 18.44% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 19.97% in Q2 2025 to a low of 60.52% in Q3 2023.
  • Historically, Net Margin has averaged 25.09% across 5 years, with a median of 24.16% in 2024.
  • Biggest five-year swings in Net Margin: skyrocketed 35751bps in 2021 and later plummeted -4670bps in 2022.
  • Year by year, Net Margin stood at 12.85% in 2021, then increased by 14bps to 11.02% in 2022, then crashed by -141bps to 26.61% in 2023, then dropped by -12bps to 29.71% in 2024, then surged by 67bps to 9.79% in 2025.
  • Business Quant data shows Net Margin for TXG at 9.79% in Q4 2025, 18.44% in Q3 2025, and 19.97% in Q2 2025.